Company profile for Corcept Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

we are leading the discovery and development of drugs that modulate the effects of cortisol Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. C...
we are leading the discovery and development of drugs that modulate the effects of cortisol Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
149 Commonwealth Drive Menlo Park, CA 94025
Telephone
Telephone
650-327-3270
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251104775200/en/Corcept-Therapeutics-Announces-Third-Quarter-Financial-Results-Oncology-Development-Programs-and-Provides-Corporate-Update

BUSINESSWIRE
04 Nov 2025

https://www.businesswire.com/news/home/20251028383789/en/Corcept-Therapeutics-to-Announce-Third-Quarter-Financial-Results-Provide-Corporate-Update-and-Host-Conference-Call

BUSINESSWIRE
28 Oct 2025

https://www.businesswire.com/news/home/20251019109551/en/Corcept-Presents-ESMO-2025-Late-Breaker-Relacorilant-Demonstrates-Benefit-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-with-Prior-PARP-Inhibitor-Treatment

BUSINESSWIRE
19 Oct 2025

https://www.businesswire.com/news/home/20251014154513/en/Corcept-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

BUSINESSWIRE
14 Oct 2025

https://www.businesswire.com/news/home/20251001096136/en/Curant-Rare-Announces-Pharmacy-Partnership-with-Corcept-Therapeutics

BUSINESSWIRE
01 Oct 2025

https://www.businesswire.com/news/home/20250922541539/en/Corcept-to-Present-New-Late-Breaking-Data-From-Pivotal-ROSELLA-Trial-of-Relacorilant-in-Platinum-Resistant-Ovarian-Cancer-at-ESMO-2025

BUSINESSWIRE
22 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty